RiboBio Re-enters 'Future Healthcare 100' List Amid Hong Kong IPO Filing

On May 9, 2024, the 8th Future Healthcare 100 (VB100) awards were grandly released in Beijing. Suzhou Ribo Life Science Co., Ltd. ("Ribo Life Science") once again ranked on the "Top 100 List of China's Innovative Pharmaceuticals and Bioproducts" in the "2024 Future Healthcare 100" selection.

The main list of the 2024 Future Healthcare 100 focuses on non-listed companies in the medical and health sector. Based on the VB100 valuation assessment model, it selects the top 100 innovative companies in terms of valuation from the fields of innovative pharmaceuticals and biologics through a process involving independent company applications, VB100 review committee evaluations, cross-reviews by supporting organizations, and final reviews by an expert committee. Additionally, the evaluation examines the growth and annual performance of candidate companies across four primary indicators—human resources, intellectual resources, key partner resources, and market performance—covering a total of 17 secondary indicators.

Ribo Life Science's achievement in this list once again honors the company, demonstrating the market's high recognition of its persistent innovative spirit and the excellent progress made in research and development and global commercialization cooperation.